Slide 1

E FFECT OF H IGH -I NTENSITY S TATIN T HERAPY ON A THEROSCLEROSIS I N N ON -I NFARCT -R ELATED A RTERIES (IBIS-4): A SERIAL MULTIVESSEL OCT STUDY Lorenz Rber, Kyohei Yamaji, Serge Zaugg, Henning Kelbaek, Marco Roffi, Maria D. Radu, Aris Moschovitis, Giovanni Pedrazzini, Lene Holmvang, Christian M. Matter, Stephane Noble, Peter Jni, Jouke Dijkstra, Konstantinos K. Koskinas, Patrick W. Serruys, Thomas F. Lscher, Masanori Taniwaki, Hector M. Garcia Garcia, Stephan Windecker Bern University Hospital IBIS 4IBIS 4 Slide 2 Disclosure Statement of Financial Interest Grant/Research Support St. Jude Medical,Switzerland Within the past 12 months, I have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial RelationshipCompany Slide 3 E FFECT OF HIGH INTENSITY STATIN THERAPY ON CLINICAL OUTCOMES IN ACS AND S TABLE CAD PATIENTS Cannon CP et al. NEJM 2004 PROVE IT TIMI 22 Balgert C et al, Lancet 2010 N>170000 patients RR reduction of 16% during 5 years per 1mmol/L LDL reduction, independent of BL LDL N=4162 Mean FUP 24 months Slide 4 -0.79% -0.99% -1.22% P S TUDY D ESIGN 1161 Acute STEMI Patients 1:1 Randomization Biomatrix vs. BMS (COMFORTABLE AMI) 11 international sites Inclusion 9/2009 - 1/2011 1 Endpoint @ 1 Year Rber L et al. JAMA 2012 Bern (60) Copenhagen (21) Geneva (13) Lugano (6) Zurich (3) 103 Acute STEMI Patients 5 Sites (N=103) Rosuvastatin 20 mg over 2 Weeks Rosuvastatin 40mg over 13 Mo 5 year follow-up 2 year follow-up IVUS RF-IVUS OCT IVUS RF-IVUS OCT TIMI >2 Hemodynamic stability Age 50% in non-IRA Anatomically suitable Slide 6 S TUDY D ESIGN Baseline IRA (not reported) Non-IRA 13 Months F/U Proximal part (>40 mm) 2 major non-IRA vessels 1 IRA vessel (stent) Matched BL - FUP Slide 7 STATINS @ F OLLOW - UP 30 days N=82 12 months N=82 Statin100%99% Rosuvastatin 10 mg1%2% 20 mg11%20% 40 mg84%72% Atorvastatin 40 mg1% 80 mg2% Slide 8 L IPID L EVELS @ 30 DAYS AND 13 MONTHS 3.3 mmol/L 1.9 mmol/L -42% p